TCRB gene rearrangements in childhood and adult precursor-B-ALL: Frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse

Leukemia

Volumn 18, Issue 12, 2004, Pages 1971-1980

  van der Velden, V H J ^a   Bruggemann M ^b   Hoogeveen, P G ^a   de Bie, M ^a   Hart, P G ^a   Raff, T ^b   Pfeifer, H ^c   Luschen S ^b   Szczepanski T ^a,d   van Wering, E R ^e   Kneba, M ^b   van Dongen, J J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF KIEL   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

Author keywords

BIOMED 2 concerted action; Minimal residual disease (MRD); Precursor B ALL; Real time quantitative PCR (RQ PCR); Stability; T cell receptor

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; ARTICLE; B CELL LEUKEMIA; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; GENE FREQUENCY; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRE B LYMPHOCYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SOUTHERN BLOTTING;

EID: 19944384539     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403505     Document Type: Article

References (61)

1. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598.
2. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
3. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
4. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000; 95: 790-794.
5. Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998; 92: 4072-4079.
6. van der Velden VH, Joosten SA, Willemse MJ, van Wering ER, Lankester AW, van Dongen JJ et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia 2001; 15: 1485-1487.
7. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409-417.
8. Foroni L, Hoffbrand AV. Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002; 15: 71-90.
9. Szczepanski T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002; 15: 37-57.
10. Goulden N, Bader P, Van Der Velden V, Moppett J, Schilham M, Masden HO et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 24-29.
11. Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002; 16 1668-1672.
12. Schrappe M. Risk-adapted therapy: lessons from childhood acute lymphoblastic leukemia. Hematol J 2002; 3: 127-132.
13. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 783-785.
14. Hoelzer D, Gokbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR et al. Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2002, 162-192.
15. Van Der Velden VH, Szczepanski T, Wijkhuijs JM, Hart PG, Hoogeveen PG, Hop WC et al. Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia 2003; 17: 1834-1844.
16. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006-2014.
17. Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000; 14: 1426-1435.
18. Bruggemann M, Droese J, Bolz I, Luth P, Pott C, von Neuhoff N et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 2000; 14: 1419-1425.
19. Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 2000; 95: 2651-2658.
20. van der Velden VH, Willemse MJ, van der Schoot CE, Hahlen K, van Wering ER, van Dongen JJ. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002; 16: 928-936.
21. van der Velden VH, Wijkhuijs JM, Jacobs DC, van Wering ER, van Dongen JJ. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 2002; 16: 1372-1380.
22. Szczepanski T, van der Velden VH, van Dongen JJ. Real-time quantitative (RQ)-PCR for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Haematologica 2002; 87 (Suppl 1): 183-191.
23. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013-1034.
24. Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002; 99: 2315-2323.
25. Willemse MJ, Seriu T, Hettinger K, d'Aniello E, Hop WC, Panzer-Grumayer ER et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99: 4386-4393.
26. van Dongen JJ, Wolvers-Tettero IL. Analysis of immunoglobulin and T cell receptor genes. Part II: Possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta 1991; 198: 93-174.
27. Felix CA, Poplack DG, Reaman GH, Steinberg SM, Cole DE, Taylor BJ et al. Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol 1990; 8: 431-442.
28. Hara J, Benedict SH, Champagne E, Mak TW, Minden M, Gelfand EW. Relationship between rearrangement and transcription of the T-cell receptor alpha, beta, and gamma genes in B-precursor acute lymphoblastic leukemia. Blood 1989; 73: 500-508.
29. Norton JD, Campana D, Hoffbrand AV, Janossy G, Couston-Smith E, Jani H et al. Correlation of immunophenotype with rearrangement of T cell antigen receptor beta and gamma genes in acute lymphoblastic leukemia of adults. Leukemia 1988; 2: 27-34.
30. Goorha R, Bunin N, Mirro Jr J, Murphy SB, Cross AH, Behm FG et al. Provocative pattern of rearrangements of the genes for the gamma and beta chains of the T-cell receptor in human leukemias. Proc Natl Acad Sci USA 1987; 84: 4547-4551.
31. Chen Z, Le Paslier D, Dausset J, Degos L, Flandrin G, Cohen D et al. Human T cell gamma genes are frequently rearranged in B-lineage acute lymphoblastic leukemias but not in chronic B cell proliferations. J Exp Med 1987; 165: 1000-1015.
32. Szczepanski T, Beishuizen A, Pongers-Willemse MJ, Hahlen K, Van Wering ER, Wijkhuijs AJ et al. Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. Leukemia 1999; 13: 196-205.
33. Aisenberg AC, Wilkes BM, Jacobson JO. Different T-cell receptor gene configurations in T-cell neoplasms and acute lymphoblastic leukemia. Cancer Res 1991; 51: 6103-6109.
34. Noss R, Kitchingman G, Cross A, Zipf TF, Antoun GR, Bernstein I et al. T cell receptor gene rearrangements in B-precursor acute lymphoblastic leukemia correlate with age and the stage of B cell differentiation. Leukemia 1988; 2: 722-727.
35. Nosaka T, Kita K, Miwa H, Kawakami K, Ikeda T, Ohno T et al. Cross-lineage gene rearrangements in human leukemic B-precursor cells occur frequently with V-DJ rearrangements of IgH genes. Blood 1989; 74: 361-368.
36. Felix CA, Reaman GH, Korsmeyer SJ, Hollis GF, Dinndorf PA, Wright JJ et al. Immunoglobulin and T cell receptor gene configuration in acute lymphoblastic leukemia of infancy. Blood 1987; 70: 536-541.
37. Dombret H, Loiseau P, Bories JC, Sigaux F. Unexpected consistent involvement of V beta gene segments in inappropriate T-cell receptor beta gene rearrangements occurring in B-lineage acute lymphoblastic leukemias. Blood 1992; 80: 2614-2621.
38. Leber BF, Amlot P, Hoffbrand AV, Norton JD. T-cell receptor gene rearrangement in B-cell non-Hodgkin's lymphoma: correlation with methylation and expression. Leuk Res 1989; 13: 473-481.
39. Tauchi T, Ohyashiki JH, Ohyashiki K, Saito M, Nakazawa S, Kimura N et al. Methylation status of T-cell receptor beta-chain gene in B precursor acute lymphoblastic leukemia: correlation with hypomethylation and gene rearrangement. Cancer Res 1991; 51: 2917-2921.
40. Davey MP, Bongiovanni KF, Kaulfersch W, Quentermous T, Seidman JG, Hershfield MS et al. Immunoglobulin and T-cell receptor gene rearrangement and expression in human lymphoid leukemia cells at different stages of maturation. Proc Natl Acad Sci USA 1986; 83 8759-8763.
41. Rowen L, Koop BF, Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 1996; 272: 1755-1762.
42. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995; 42: 455-500.
43. van Dongen JJM, Langerak AW, Bruggemann M, Evans PAS, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations. Leukemia 2003; 17: 2257-2317.
44. Bruggemann M, van der Velden VHJ, Raff T, Droese J, Ritgen M, Pott C et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease (MRD) in childhood and adult T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 2004; 18: 709-719.
45. Verhagen OJ, Wijkhuijs AJ, van der Sluijs-Gelling AJ, Szczepanski T, van der Linden-Schrever BE, Pongers-Willemse MJ et al. Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques. Leukemia 1999; 13: 1298-1299.
46. Szczepanski T, van der Velden VHJ, Raff T, Jacobs DCH, van Wering ER, Brüggemann M et al. Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of secondary T-ALL. Leukemia 2003; 17: 2149-2156.
47. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13 110-118.
48. Szczepanski T, Willemse MJ, van Wering ER, van Weerden JF, Kamps WA, van Dongen JJ. Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 2001; 15: 1415-1423.
49. Szczepanski T, van der Velden VHJ, Hoogeveen PG, De Bie M, Jacobs DCH, Van Wering ER et al. Vδ2-Jα gene rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood 2004; 103: 3798-3804.
50. Lefranc MP. IMGT databases, web resources and tools for immunoglobulin and T cell receptor sequence analysis. http://imgt.cines.fr. Leukemia 2003; 17: 260-266.
51. Langerak AW, Wolvers-Tettero IL, van Dongen JJ. Detection of T cell receptor beta (TCRB) gene rearrangement patterns in T cell malignancies by Southern blot analysis. Leukemia 1999; 13: 965-974.
52. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
53. Droese J, Langerak AW, Groenen PJTA, Bruggemann M, Neumann P, Wolvers-Tettero IL et al. Validation of Biomed-2 multiplex PCR tubes for detection of TCRB gene rearrangements in T-cell malignancies. Leukemia 2004; 18: 1531-1538.
54. Huebner S, Cazzaniga G, Flohr T, van der Velden VHJ, Konrad M, Basso G et al. High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1 positive leukemias. Leukemia 2004; 18: 84-91.
55. Fey MF, Tobler A, Stadelmann B, Hirt A, Theilkas L, Khandjian EW et al. Immunogenotyping with antigen receptor gene probes as a diagnostic tool in childhood acute lymphoblastic leukaemia. Eur J Haematol 1990; 45: 215-222.
56. Dyer MJ. T-cell receptor delta/alpha rearrangements in lymphoid neoplasms. Blood 1989; 74: 1073-1083.
57. Langerak AW, van Den Beemd R, Wolvers-Tettero IL, Boor PP, van Lochem EG, Hooijkaas H et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood 2001; 98: 165-173.
58. Beishuizen A, Verhoeven MA, van Wering ER, Hahlen K, Hooijkaas H, van Dongen JJ. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994; 83: 2238-2247.
59. Li A, Zhou J, Zuckerman D, Rue M, Dalton V, Lyons C et al. Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood 2003; 102: 4520-4526.
60. Germano G, del Giudice L, Palatron S, Giarin E, Cazzaniga G, Biondi A et al. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia 2003; 17: 1573-1582.
61. van Wering ER, van der Linden-Schrever BE, van der Velden VH, Szczepanski T, van Dongen JJ. T-lymphocytes in bone marrow samples of children with acute lymphoblastic leukemia during and after chemotherapy might hamper PCR-based minimal residual disease studies. Leukemia 2001; 15: 1301-1303.